Today concludes this year’s American Society of Clinical Oncology (ASCO) annual meeting, which began on Friday in Chicago.  However, yesterday was the last day with any multiple myeloma-related sessions.

During yesterday’s poster session, important new research findings were summarized on posters throughout a large conference hall.

The studies were on a wide variety of myeloma-related topics ranging from new treatments being developed for myeloma, to currently used regimens, to secondary cancers, to precursor myeloma diseases, and much more.

This update covers some of the myeloma-related studies presented during the poster…

Today was the second day of the American Society of Clinical Oncology (ASCO) annual meeting.  Although the day has not been as busy with myeloma-related presentations as tomorrow and Monday will be, there still were some interesting presentations and discussions.

The Beacon published an update earlier today with news from a morning poster session that featured several presentations related to multiple myeloma (see related Beacon news).

This article covers material from an early-afternoon education session that was titled: ”Controversies in Myeloma: Induction, Transplant, and Maintenance.”

The education session included three…

The 48th annual meeting of the American Society of Clinical Oncology (ASCO) will take place Friday, June 1, through Tuesday, June 5, in Chicago.

More than 25,000 clinical specialists from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care. The theme for this year’s meeting is “Collaborating to Conquer Cancer.”

The meeting will include many presentations and seminars focused specifically on multiple myeloma. The ASCO website currently lists nearly 50 myeloma-based presentations (included under “lymphoma and plasma cell…

The results of the three major clinical trials investigating Revlimid maintenance therapy were published yesterday in three separate articles in the New England Journal of Medicine.

The articles were accompanied by an editorial summarizing the study findings and discussing their significance for the treatment of multiple myeloma patients.

All three clinical trials involved newly diagnosed multiple myeloma patients.  The patients in the trials first underwent initial treatment that in some cases included Revlimid (lenalidomide).  In two of the three trials, the initial treatment also included a stem cell transplant.…

The U.S. Food and Drug Administration earlier today issued an extensive update regarding the risk of developing a second cancer while being treated with Revlimid.

The update comes on the heels of a change the Food and Drug Administration (FDA) made to the prescribing information for Revlimid (lenalidomide) in March of this year.

The change involved the addition of a warning that patients being treated with Revlimid have an increased risk of developing a second cancer (see related Beacon news).

Today’s update by the FDA includes more specific details…